Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses

Author:

Messori Andrea1ORCID,Damuzzo Vera2,Rivano Melania3ORCID,Cancanelli Luca2ORCID,Di Spazio Lorenzo4,Ossato Andrea5ORCID,Chiumente Marco6ORCID,Mengato Daniele7ORCID

Affiliation:

1. Unità di HTA, Regione Toscana, 50139 Firenze, Italy

2. Dipartimento Politiche del Farmaco, Azienda ULSS 2 Marca Trevigiana, 31100 Treviso, Italy

3. Farmacia Ospedaliera, Ospedale Binaghi, 09121 Cagliari, Italy

4. Farmacia Ospedaliera Nord, Ospedale Santa Chiara di Trento, Azienda Provinciale per i Servizi Sanitari (APSS), 38122 Trento, Italy

5. Scuola di Specializzazione in Farmacia Ospedaliera, Università di Padova, 35128 Padova, Italy

6. Società Italiana di Farmacia Clinica e Terapia (SIFaCT), 10123 Torino, Italy

7. Farmacia Ospedaliera, Azienda Ospedale Università di Padova, 35128 Padova, Italy

Abstract

In the area of evidence-based medicine, the IPDfromKM-Shiny method is an innovative method of survival analysis, midway between artificial intelligence and advanced statistics. Its main characteristic is that an original software investigates the Kaplan-Meier graphs of trials so that individual-patient data are reconstructed. These reconstructed patients represent a new form of original clinical material. The typical objective of investigations based on this method is to analyze the available evidence, especially in oncology, to perform indirect comparisons, and determine the place in therapy of individual agents. This review examined the most recent applications of the IPDfromKM-Shiny method, in which a new web-based software—published in 2021—was used. Reported here are 14 analyses, mostly focused on oncological treatments. Indirect comparisons were based on overall survival or progression free survival. Each of these analyses provided original information to compare treatments with one another and select the most appropriate depending on patient characteristics. These analyses can also be useful to assess equivalence from a regulatory viewpoint. All investigations stressed the importance of heterogeneity to better interpret the evidence generated by IPDfromKM-Shiny investigations. In conclusion, these investigations showed that the reconstruction of individual patient data through this online tool is a promising new method for analyzing trials based on survival endpoints. This new approach deserves further investigation, particularly in the area of indirect comparisons.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3